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Introduction
Left ventricular (LV) systolic function is an independent predictor 
of outcome after aortic valve replacement (AVR) in patients with 
severe aortic stenosis (AS).1)2) Previous studies have mostly shown 
that patients with a reduced ejection fraction (EF) and severe AS have 
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Subjects and Methods: We analyzed 41 patients (24 males, 63.1±8.7 years) with preserved LV systolic function who were scheduled to 
undergo AVR for severe AS. All patients were examined with transthoracic echocardiography (TTE), CMR before and after AVR (in the hos-
pital) and serial TTEs (at 6 and 12 months) were repeated.
Results: The group with LGE (LGE+) showed greater wall thickness (septum, 14.3±2.6 mm vs. 11.5±2.0 mm, p=0.001, posterior; 14.3±2.5 
mm vs. 11.4±1.6 mm, p<0.001), lower tissue Doppler image (TDIS’, 4.4±1.4 cm/s vs. 5.5±1.2 cm/s, p=0.021; TDI E’, 3.2±0.9 cm/s vs. 4.8±1.4 
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48.3±5.0 mm vs. 46.5±3.4 mm, p=0.019). Moreover, E/e’ (at 12 months) showed further improved LV filling pressure (16.0±6.6 vs. 12.3±4.3, 
p=0.001) compared with pre-AVR. However, LGE+ showed no significant improvement. 
Conclusion: The absence of LGE is associated with favorable improvements in LV geometry and filling pressure. TDI E’ is an independent 
determinant of LGE in patients with severe AS and preserved LV systolic function. (Korean Circ J 2014;44(5):312-319)
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higher operative mortality and poor survival benefit versus those 
with normal EF.3-6) However, patients with reduced EF represent <5% 
of the population of patients with AS,2)4) and most patients who un-
derwent AVR have preserved LV systolic function. Although dobuta-
mine stress echocardiography is used for risk stratification of pa-
tients with reduced EF and severe AS,7)8) it is unclear what the best 
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method is in patients with preserved EF and severe AS.
Severe AS causes LV pressure overload and results in myocardial 
fibrosis and impairment of myocyte ultrastructure.9-11) Also, it has 
been shown that the amount of myocardial fibrosis and myocyte 
degeneration affect LV systolic and diastolic dysfunction.9)12)13) With 
the development of cardiac magnetic resonance imaging (CMR), it 
was seen that late gadolinium enhancement (LGE) showed a good 
correlation with the degree of myocardial fibrosis by histopatholo-
gy.14)15) Moreover, the amount of myocardial fibrosis was found to 
be an independent predictor of clinical outcome after AVR, and it 
had a meaningful association with LV functional remodeling.14)15) A 
problem with this analysis, however, is that histopathological mea-
surement of fibrosis before AVR is too invasive for predicting long-
term outcomes of patients with severe AS. Also, CMR comes at a 
high medical cost and cannot be used in patients with an intracar-
diac device. The purpose of our study was to investigate the differ-
ences between LV geometric changes following AVR according to 
the presence of LGE on CMR and to evaluate echocardiographic pre-
dictors of LGE in patients with severe AS and preserved LV systolic 
function.
Subjects and Methods
Study population and protocol 
We enrolled 41 patients who were scheduled for an AVR due to 
severe AS, but who had preserved LV systolic function (EF ≥50%) 
from January 2010 to April 2012. Severe AS was defined as having 
an aortic valve area ≤1.0 cm2 and having symptoms such as dys-
pnea on exertion or syncope.16)17) All patients were evaluated by 
CMR, transthoracic echocardiography (TTE), and coronary angiogra-
phy (CAG) before undergoing AVR. The exclusion criteria were any 
of the following: 1) having reduced LV systolic function (EF <50%), 
2) having luminal narrowing of more than 50% by CAG, 3) having 
valvular disease more than grade I except AS, 4) having had a previ-
ous cardiac surgery, 5) having a history of percutaneous coronary in-
tervention, or 6) having a history of myocardial infarction.
This study progressed prospectively after the enrollment of pa-
tients. All enrolled patients were evaluated by TTE, CMR, and CAG 
within 1 month before AVR, and the post-AVR TTE was conducted 
within 2 weeks after AVR (Fig. 1). Eight patients with EF <50% were 
excluded. Finally, 41 enrolled patients received follow-up appoint-
ments at an outpatient clinic. Repeat post-AVR TTEs were performed 
6 months and 12 months after AVR.
This study protocol was approved by the Institutional Review 
Board of the Yonsei University Health System. All patients provided 
written informed consent.
Standard echocardiographic measurements
Chamber size {left atrial volume index (LAVI), LA dimension, wall 
thickness of the LV, LV mass index (LVMI), and LV end diastolic di-
mension (LVEDD)/LV end systolic dimension (LVESD)}, flow pattern 
{trans mitral flow velocity (E wave, A wave), deceleration time}, and 
tissue Doppler imaging (TDI) of the mitral annular septal area {peak 
diastolic velocity (e’), peak systolic velocity (S’)} were measured ac-
cording to the American Society of Echocardiography (ASE) guide-
lines.18-20) Two-dimensional echocardiographic assessment of LV 
volume and LV EF was performed in apical two- and four-chamber 
images. The endocardial border at both the end-diastolic and end-
systolic frame was traced manually, and LV end diastolic volume (LV-
EDV), LV end-systolic volume (LVESV), and LVEF were calculated 
using the single-plane Simpson formula. LV mass was calculated 
from LV linear dimensions, as recommended by of ASE. The poste-
rior wall thickness (PWTd) and septal wall thickness were measured 
at end diastole. Relative wall thickness (RWT) was calculated with 
the formula (2×PWTd)/LVEDD. LAVI was also measured from the 
biplane method of disks (modified Simpson’s method) using apical 
two and four chamber views at ventricular end systole (maximum 
LA size). All echocardiographic parameters were determined by a so-
nographer who was blinded to the patient’s information. The results 
were confirmed by a second expert echocardiographer who was un-
aware of the patients’ clinical information. 
Magnetic resonance imaging protocol
All patients underwent CMR within 1 month prior to AVR. CMR 
Enrolled patients
permission
(n=49)
TTE
cMRI
CAG
TTE f/u
(2 weeks, 
6 months, 
12 months)
(n=41)
8 patients (EF<50%)
were excluded
Within
2 weeks
Within
2 weeks
2 weeks
6 months
12 months
AVR
Fig. 1. Evaluation of the progress of patients enrolled in the study. TTE: transthoracic echocardiography, CMR: cardiac magnetic resonance image, CAG: 
coronary angiography, AVR: aortic valve replacement, f/u: follow up, EF: ejection fraction.
314 Severe Aortic Stenosis and Late Gadolinium Enhancement
http://dx.doi.org/10.4070/kcj.2014.44.5.312 www.e-kcj.org
was performed on a 1.5 T cardiac magnetic resonance system (Achie-
va 1.5 T; Philips Medical Systems 5680 DA, the Netherlands). The 
myocardium of the LV was evaluated in the short axis view,21) and 
divided into base level (six segments), mid level (six segments) and 
apex (four segments). Consequently the entire myocardium of the 
LV was analyzed as a total of 16 segments (Fig. 2). The appropriate 
inversion time of LGE CMR image was determined by inversion 
scout (TI-scout) with the Look-Locker technique. The mean inversion 
time for normal myocardium was 250–300 ms. All CMR (cine and 
LGE images) images of the entire LV were acquired with a 10-mm 
slice without a gap. The volume of the LV was determined by planim-
etry from a series of short-axis acquisitions covering the LV com-
pletely from the apex to the base. Quantification of LVESV, LVEDV, 
and EF were performed on the short-axis series with manual con-
tour segmentation of the endocardial borders. The total LV stroke 
volume was obtained by subtracting the LV end-systolic volume 
from the LV end-diastolic volume. Each image was acquired 10–15 
minutes after injection of 0.2 mmol/kg body weight gadotertate 
dimeglumine (Dotarem; Guerbet, Roissy CdG Cedex, Paris, France) to 
measure LGE from CMR. Endocardial and epicardial borders were 
traced semi-automatically, and LGE was defined as the pixels 
above the pre-determined threshold using the Q-MASS software 
(QMASS MR 7.4, Medis Medical Imaging Systems bv, Leiden, the 
Netherlands).15)22) The pre-determined threshold was defined as 
mean signal intensity (SI) total myocardium+2 standard deviation 
(SD) of mean SI of a non-diseased area without LGE+2SD of mean 
SI of air (Fig. 2).15) 
Statistical analyses
The normally distributed continuous variables are expressed as 
means±SD. We compared baseline characteristics and echocardio-
graphic parameters between patients with and without LGE. Sta-
tistical significance (p<0.05) for comparisons was assessed using 
the unpaired two-tailed Student’s t-test for normally distributed 
continuous variables and the χ2 test for nominal variables. All echo-
cardiographic parameters were compared sequentially to the data 
from pre-AVR, post-AVR, 6-month follow-up, and 12-month follow-
up analyses using a paired t-test and a mixed linear model accord-
ing to the presence of LGE (significance defined as p<0.05).
Univariate and multivariate logistic regression analyses were used 
to confirm which echocardiographic parameters were associated 
with the presence of LGE (p<0.05). Variables selected for multivari-
ate analysis were those with p<0.05 in the univariate analysis or 
were thought clinically to be associated with the presence of LGE. 
Variance inflation factors were used to measure co-linearity in mul-
tiple regression analyses.
Results
Baseline characteristics
In total, 49 patients were screened and eight with EF <50% were 
excluded before AVR. Finally 41 patients (24 males, 63.1±8.7 years) 
completed follow-up at 6 and 12 months post-AVR. LGE was de-
tected in 12 (29.3%) patients. The main detection locations for LGE 
were the inferior wall (81.8%), the inferior septum (72.7%), and the 
mid-level (100%) of the LV (Fig. 3). Bicuspid AV was detected in 15 
(36.6%) patients as the cause of AS.
Table 1 shows baseline characteristics for the initially enrolled 
Fig. 2. The myocardium of the LV was evaluated in short axis view, and divided into base level (6 segments), mid level (6 segments), and apex (4 segments). 
The entire myocardium of the LV was analyzed as a total of 16 segments. LV: left ventricular, LAD: left anterior descending, LCX: left circumplex artery, RCA: 
right coronary artery.
Base (6) Mid-level (6) Apex (4)
Fig. 3. Bull’s eye map image regarding late gadolinium enhancement (left: 
short axis, right: long axis).
Anterioseptal (36.4%)
Septal (72.7%)
Inferior (81.8%) Posterior (54.5%)
Lateral (54.5%)
Anterior (36.4%)
Base (54.5%) Mid level (100%)
Apex (54.5%)
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Table 1. Baseline characteristics according to LGE by CMR
All (n=41) LGE (-) (n=29) LGE (+) (n=12) p
Age (years) 63.1±8.7 62.1±9.1 65.4±7.5 0.278
Male (n, %) 24 (58.5) 17 (58.6) 7 (58.3) 0.987
Diabetes mellitus (n, %) 3 (7.3) 1 (3.4) 2 (16.7) 0.265
Hypertension (n, %) 15 (36.6) 9 (31.0) 6 (50.0) 0.212
Dyslipidemia (n, %) 5 (12.2) 3 (10.3) 2 (16.7) 0.943
Syncope Hx (n) 1 0 1 -
NYHA III, IV (n, %) 24 (57.9) 18 (62.1) 6 (50.0) 0.167
Medication (pre-OP) (%)
ACE inhibitor or ARB 12 (29.3) 11 (37.0) 1 (8.3) 0.089
Beta blocker 9 (22.0) 6 (20.7) 3 (25.0) 0.789
Calcium channel blocker 7 (17.1) 4 (13.8) 3 (25.0) 0.383
Medication (post-OP) (%)
 ACE inhibitor or ARB 23 (56.1) 16 (55.2) 7 (58.3) 0.956
Beta blocker 20 (48.8) 15 (52.0) 5 (41.7) 0.729
Calcium channel blocker 11 (26.8) 6 (20.7) 5 (41.7) 0.092
Echocardiography
RWMA (n, %) 0 0 0 -
Ejection fraction (%) 68.0±8.2 69.4±7.6 64.5±8.8 0.091
LV end diastolic diameter (mm) 47.9±5.3 48.5±5.0 46.6±5.9 0.336
LV end systolic diameter (mm) 30.9±4.9 30.8±4.6 31.4±5.8 0.744
Peak aortic pressure gradient (mm Hg) 87.9±31.4 83.7±32.9 97.9±26.4 0.214
Mean aortic pressure gradient (mm Hg) 55.6±20.4 52.8±20.0 62.2±20.8 0.205
Aortic valve area (cm2) 0.7±0.3 0.7±0.3 0.7±0.2 0.486
LV mass index (g/m2) 135.7±34.4 127.7±33.1 156.0±30.4 0.019
LA volume index (mL/m2) 38.5±20.8 38.1±23.2 39.5±14.1 0.858
Deceleration time (ms) 237.3±53.5 223.5±46.4 266.0±57.8 0.021
E (cm/s) 0.7±0.2 0.7±0.2 0.7±0.2 0.755
A (sm/s) 1.0±0.3 0.9±0.3 1.0±0.3 0.495
TDI e (cm/s)’ 4.3±1.5 4.8±1.4 3.2±0.9 0.002
TDI A’ (cm/s) 7.6±2.2 8.1±1.9 6.4±2.4 0.041
TDI S' (cm/s) 5.1±1.4 5.5±1.2 4.4±1.4 0.021
E/e’ 17.4±8.2 15.4±6.3 21.8±10.3 0.066
CMR findings
LVM (g) 152.9±58.7 144.1±60.0 172.2±55.6 0.347
LVMI (g/m2) 83.8±36.6 74.3±34.5 102.7±36.0 0.123
LVEDV (mL/BSA) 83.1±23.2 81.9±19.4 86.5±33.3 0.721
LVESV (mL/BSA) 31.9±15.6 29.6±11.2 38.4±24.1 0.348
LVM/LVEDV (g/mL) 1.2±0.6 1.0±0.4 1.5±0.8 0.087
Follow-up findings
SBP (mm Hg) 123.1±19.6 121.2±19.6 127.9±19.6 0.343
DBP (mm Hg) 75.7±12.0 75.0±12.3 77.4±11.5 0.595
Mechanical valve (%) 20 (52.6) 16 (59.3) 4 (36.4) 0.200
Indexed EOA (cm2/m2) 1.1±0.2 1.1±0.3 1.0±0.2 0.384
LGE: late gadolinium enhancement, CMR: cardiac magnetic resonance image, NYHA: New York Heart Association, ACE: angiotensin converting enzyme, ARB: 
angiotensin receptor blocker, RWMA: regional wall motion abnormality, LV: left ventricle, LA: left atrial, TDI: tissue Doppler imaging, LVM: left ventricle mass, 
LVMI: left ventricle mass index, LVEDV: left ventricle end diastolic volume, LVESV: left ventricle end-systolic volume, SBP: systolic blood pressure, DBP: dia-
stolic blood pressure, EOA: effective orifice area
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patients. Neither age nor gender was significantly different between 
the two groups. Also, history of diabetes mellitus, hypertension, and 
dyslipidemia were similar in both groups. Use of medications that 
could have an effect on LV geometry and filling pressure did not 
differ significantly after the operation. However, echocardiographic 
findings showed significant differences between the two groups. 
The thickness of the inter-ventricular septum (14.3±2.6 mm vs. 
11.5±2.0 mm, p=0.001) and of the LV posterior wall (14.3±2.5 mm 
vs. 11.4±1.6 mm, p<0.001) were greater in LGE+ patients.
Tissue Doppler imaging offered the most important findings: 
LGE+ patients had lower e’ (3.2±0.9 cm/s vs. 4.8±1.4 cm/s, p=0.002), 
S’ (4.4±1.4 cm/s vs. 5.5±1.2 cm/s, p=0.021), and higher E/e’ (21.8± 
10.3 vs. 15.4±6.3, p=0.066). However, the size of the cardiac cham-
bers, the aortic valve area, and the pressure gradient via the aortic 
valve and LV systolic function were not significantly different (Table 1).
Left ventricular remodeling after aortic valve replacement 
according to the presence of late gadolinium enhancement
The sequentially measured post-AVR echocardiographic param-
eters were compared with those measured before AVR. LVEDD and 
RWT were decreased significantly after AVR in patients without LGE, 
but there was no significant decrease in patients with LGE. LVMI 
was decreased regardless of LGE (Fig. 4). E/e’, an index of LV filling 
pressure, was improved significantly in LGE- patients up to 12 
months (from 16.0±6.6 to 12.3±4.3, p=0.001) after AVR. Also, E/e’ at 
12 months showed a significant difference between LGE- and LGE+ 
(12.3±4.3 vs. 19.9±8.3, p=0.026) compared with those prior to AVR 
(15.4±6.3 vs. 21.8±10.3, p=0.066) (Fig. 5, Table 1). However, no im-
provement was observed of E/e’ in LGE+ patients. Additionally, in-
creases in the LV EF showed no significant change between the 
groups through the 12-month follow-up period (Fig. 5).
Multivariate logistic regression analysis on the presence of 
late gadolinium enhancement
Tissue Doppler imaging e’ (odds ratio=0.078, 95% confidence in-
terval=0.007–0.888, p=0.040) was independently associated with 
LGE by CMR in patients with severe AS (Table 2).
Discussion
This prospective study showed that the presence of LGE for risk 
stratification before AVR in patients with severe AS could play an 
Fig. 5. Change in left ventricular systolic function and filling pressure after aortic valve replacement. Group 1, 2, 3, and 4: pre-OP, post OP, 6 months post-
OP, and 12 months post-OP, respectively. Error bars: 95% confidence interval. *p<0.05. LGE: late gadolinium enhancement, LVEF: left ventricle ejection fraction.
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important role in predicting the long-term outcome and improve-
ment of LV remodeling after AVR. CMR, a non-invasive method, 
makes it possible to predict myocardial fibrosis and LGE,14)15) and we 
found that the presence of LGE had effects on poor improvement 
of LV filling pressure in patients with severe AS. However, unlike pre-
vious studies,14)15) this study showed that some echocardiographic 
parameters were associated with the presence of LGE; these findings 
can be used clinically in patients with contraindications, as deter-
mined by CMR. TDI E’, especially, is a clinically useful clue of risk st-
ratification before AVR in patients with severe AS and preserved LV 
systolic function.
Myocardial fibrosis by biopsy and late gadolinium 
enhancement by cardiac magnetic resonance imaging
Previous studies reported that LGE in CMR reflected myocardial 
fibrosis, as determined by histopathology, in patients with severe 
aortic valve disease, including aortic regurgitation.15) Additionally, 
LGE in CMR has also been found to indicate necrosis by myocardial 
ischemia,23-25) variable changes by non-ischemic cardiomyopa-
thy,26-28) and hypertrophic cardiomyopathy,29) as well as myocardial 
fibrosis. A recent report showed that LGE measurements from CMR 
were overestimated versus the amount of fibrosis estimated by pa-
thology.22) Moreover myocardial fibrosis associated with severe AS 
did not show a diffuse pattern, but rather a patch-like appearance, 
and was usually located at the basal area of the LV.14) Based on these 
results, it can be concluded that cardiac biopsy to determine the 
presence of myocardial fibrosis before AVR will yield a high number 
of false negative results.
Late gadolinium enhancement by cardiac magnetic resonance 
imaging and left ventricular remodeling after aortic valve 
replacement
As mentioned previously, LV systolic function is an important pre-
dictor of operation mortality and clinical outcome. The risk stratifi-
cation of patients with reduced EF and severe AS has been evaluated 
by various methods.7)8) However, although patients with preserved 
LV systolic function represent a large proportion of those with se-
vere AS, evaluation for risk stratification prior to an operation is not 
enough. Furthermore, there has been no report showing a direct as-
sociation between the presence of LGE and geometric remodeling of 
LV after AVR among patients with preserved LV systolic function.
The amount of myocardial fibrosis that was measured during the 
operation has an important association with long-term post-AVR 
outcome in patients with severe AS.14) With the availability of CMR, 
it is important to use LGE to determine risk stratification before AVR 
in patients with severe AS. This study showed that the presence of 
LGE was associated with poor improvement of LV geometry and fill-
ing pressure after AVR, especially in patients with preserved LV sys-
tolic function.
Clinical implications of echocardiography to predict late 
gadolinium enhancement and limitations of cardiac magnetic
resonance imaging
Cardiac magnetic resonance still has important limitations, such 
as its high medical cost, contraindication in patients with an intra-
cardiac device, poor availability, and limited use in patients with 
claustrophobia. Thus, we compared echocardiographic parameters 
with the presence of LGE as measured by CMR. As mentioned in the 
American College of Cardiology/American Heart Association/Euro-
pean Society of Cardiology guidelines,16)17) most patients with se-
vere AS experience AVR during the period in which EF is preserved 
(≥50%). In this study, the aortic valve area, pressure gradient, and 
the size of cardiac chambers did not differ significantly according 
to the presence of LGE. LV wall thickness also did not appear to have 
important implications, based on the multivariate analysis. In the 
analysis of tissue Doppler imaging, TDI e’ and S’ showed significant 
differences between patients with LGE and those without LGE; TDI e’ 
was independently associated with LGE after controlling related fac-
tors. Consequently, patients with severe AS and preserved LV systolic 
function also had reduced TDI e’, which suggests a diastolic abnor-
mality of the LV,18)20) and may be a surrogate marker of LGE in CMR.
Limitations
We analyzed the changes in LV geometry and the improvement 
of systolic function and filling pressure after AVR according to the 
presence of LGE in patients with severe AS and preserved LV sys-
tolic function. We did not, however, look for a difference according 
to the degree of LGE. Previous studies have classified ‘mild’ LGE 
according to the amount of LGE,14) but ‘mild’ LGE did not have any 
definite clinical implication in terms of risk stratification. Thus, fur-
ther evaluations of the severity of LGE should be performed after 
Table 2. Multivariate logistic regression analysis on LGE by CMR
OR 95% CI p
Age 1.002 0.828–1.214 0.981
Male 0.626 0.046–8.610 0.726
Deceleration time 1.016 0.988–1.044 0.259
LVMI 1.023 0.982–1.067 0.272
TDI S’ 1.152 0.202–6.576 0.873
TDI A’ 0.591 0.215–1.627 0.309
TDI e’ 0.078 0.007–0.888 0.040
E/e’ 0.864 0.591–1.264 0.453
LGE: late gadolinium enhancement, CMR: cardiac magnetic resonance im-
age, OR: odds ratio, CI: confidence interval, LVMI: left ventricular mass in-
dex, TDI: tissue Doppler imaging
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the enrollment of additional patients. There was no mortality in 
our study after AVR during the 12 months of follow-up, so we could 
not analyze mortality outcomes according to the presence of LGE.
Conclusions
The presence of LGE, as measured with CMR, is associated with 
poor improvement of LV geometry and filling pressure after AVR in 
patients with severe AS and preserved LV systolic function. Reduced 
TDI E’ is an independent associate of LGE and can be measured 
noninvasively.
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